GDTC logo

CytoMed Therapeutics Limited (GDTC) Cash From Operations

Annual CFO

-$2.56 M
-$1.54 M-151.88%

31 December 2023

GDTC Cash From Operations Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

GDTC Cash From Operations Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-151.9%--
3 y3 years-314.8%--
5 y5 years---

GDTC Cash From Operations High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-314.8%at low
5 y5 years-314.8%at low
alltimeall time-314.8%at low

CytoMed Therapeutics Limited Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2023
-$2.56 M(+151.9%)
-
-
Dec 2022
-$1.01 M(-20.4%)
-
-
DateAnnualQuarterlyTTM
Dec 2021
-$1.27 M(+106.9%)
-
-
Dec 2020
-$616.10 K
-
-

FAQ

  • What is CytoMed Therapeutics Limited annual cash flow from operations?
  • What is the all time high annual CFO for CytoMed Therapeutics Limited?
  • What is CytoMed Therapeutics Limited annual CFO year-on-year change?

What is CytoMed Therapeutics Limited annual cash flow from operations?

The current annual CFO of GDTC is -$2.56 M

What is the all time high annual CFO for CytoMed Therapeutics Limited?

CytoMed Therapeutics Limited all-time high annual cash flow from operations is -$616.10 K

What is CytoMed Therapeutics Limited annual CFO year-on-year change?

Over the past year, GDTC annual cash flow from operations has changed by -$1.54 M (-151.88%)